Design, synthesis and activity evaluation of quinolinone derivatives as EZH2 inhibitors
Authors:
- 4 April 2024
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 105, 129726
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Jiangsu Province (BK20161438)
This publication has 23 references indexed in Scilit:
- Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure–Activity Relationships Insights and Evolution ProspectsJournal of Medicinal Chemistry, 2022
- The molecular mechanisms and therapeutic potential of EZH2 in breast cancerLife Sciences, 2021
- Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin’s LymphomaACS Medicinal Chemistry Letters, 2018
- EZH2 alterations in follicular lymphoma: biological and clinical correlationsBlood Cancer Journal, 2017
- Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell LymphomasJournal of Medicinal Chemistry, 2016
- Enhancer of zeste homolog 2 (EZH2) expression in bladder cancerUrologic Oncology: Seminars and Original Investigations, 2016
- PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and DiseaseBiochemistry, 2016
- Targeting histone lysine methylation in cancerPharmacology & Therapeutics, 2015
- The Polycomb complex PRC2 and its mark in lifeNature, 2011
- Roles of the EZH2 histone methyltransferase in cancer epigeneticsMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008